The FDA and an academic research consortium have released a framework for communicating high-throughput sequencing computations and data analysis.
The consortium is collecting data from different omics streams for a cohort of individuals with autism spectrum disorders with the long-term goal of improving treatment.
Investigators intend to genotype the biorepository using Illumina arrays with the aim of identifying markers that can be used to inform treatment and prevention efforts.
The companies will recruit and track a cohort of women to study environmental, genetic, and lifestyle factors that may contribute to fertility outcomes.
The researchers will use single-cell genomics and other approaches to generate information that could ultimately be used to diagnose, monitor, and treat disease.
The Finnish bioinformatics firm will aid European researchers and animal-focused diagnostics companies in developing a functional annotation of the dog genome.
The research aims to validate new predictive tests that would enable development of diagnostic and therapeutic solutions to fight sepsis.
The large-scale study is designed to advance personalized medicine for pancreatic cancer to help meet the organization's goal of doubling patient survival rates by 2020.
The group this week published a set of initial guidelines for antibody validation meant as recommendations in advance of a larger meeting later this month.
The consortium is made up of Genome Profiling, Rob Knight's UCSD lab, KromaTid, Metabolon, and Orig3n, and is sponsored by a new company called Interome.
New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.
Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.
La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.
In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.